Angiotensin receptor blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
The review found no eligible studies for this question.
1 finding from 1 review
Total mortality · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors showed no clear difference in total mortality compared with all angiotensin receptor blockers (ARBs) (moderate certainty).
1 finding from 1 review
Cardiovascular events · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors showed no clear difference in total cardiovascular events compared with all angiotensin receptor blockers (ARBs) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors leads to lower withdrawal due to adverse effects compared with all angiotensin receptor blockers (ARBs) (high certainty).
1 finding from 1 review
Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension
Antihypertensive drug leads to lower total mortality Mean duration of 3.8 years compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower coronary heart disease mortality and morbidity Mean duration of 2.9… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults 60 years or older with primary hypertension
Antihypertensive drug may leads to higher withdrawals due to adverse effects Mean duration of 4.6 years compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Beta‐blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Calcium channel blocker (any dose) Mean duration of 3 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review